Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC.

JTO Clin Res Rep · 2025 · PMC12629915 · PMID 41280949

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

These 29 patients were treated during the following time frame: seven (24%) from 2017 to 2019, 12 (41%) from 2020 to 2021, and 10 (35%) from 2022 to 2023, reflecting an increasing trend in the use of ID-chemo-ICI followed by cCRT over time.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.